Navigation Links
Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference
Date:3/5/2012

RESEARCH TRIANGLE PARK, N.C., March 5, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 3:00 pm ET at The Boston Marriott Copley Place in Boston, Massachusetts.

Mr. Moch's presentation will include an update on the company's clinical pipeline, which includes its lead development program, CMX001.  CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA viruses (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release. CMX001 recently announced results for Study 201, a Phase 2 double-blind, placebo-controlled trial which evaluated the safety, tolerability and ability of CMX001 to prevent or control cytomegalovirus (CMV) disease in 230 CMV-seropositive allogeneic stem cell transplant recipients. CMX001 had a statistically significant benefit versus placebo in preventing CMV viremia and/or CMV disease 13 weeks post-transplant. These data were presented during the "Best Abstracts Plenary Session" at the 2012 BMT Tandem Meetings on February 3rd in San Diego.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. Utilizing proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs.

The company's lead candidate, CMX001, is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofo
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015  Psychemedics Corporation (NASDAQ: PMD ), ... years, announced the addition of 2 new drugs to ... abuse concerns, the addition of Oxymorphone was made to ... as an option to the Amphetamine panel. ... "Sadly, more and more prescription drugs are being abused. ...
(Date:6/2/2015)... 2, 2015  Accuray Incorporated (Nasdaq: ARAY ), ... present at the Goldman Sachs 36th Annual Global Healthcare ... on Wednesday, June 10, 2015 at 4:00pm PT. ... will be available on the Investor Relations page of ... replay of the presentation will begin approximately one hour ...
(Date:6/2/2015)... , Minn. and WELLESLEY, Mass., June 2, 2015 /PRNewswire/ ... principal owner, Ampersand Capital Partners (Ampersand), announced the ... operation of Array BioPharma Inc. (Array).  Accuratus was ... Eagan, MN acquired Microtest ... GLP analytical and microbial testing services to the ...
Breaking Medicine Technology:Psychemedics Announces Addition Of FDA Cleared Drugs 2Psychemedics Announces Addition Of FDA Cleared Drugs 3Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 2Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 3
... NEW YORK, Oct. 25 2011 Help Remedies, the ... bold statement "Take Less", calling out big pharma for ... OTC drugs. In a category that traditionally promotes more, ... is communicating a unique message, that less – less ...
... 25, 2011 Reportlinker.com announces that a ... its catalogue: Global Eyeglasses ... This report analyzes the worldwide ... US$ Million by the following Product Segments: ...
Cached Medicine Technology:Help Remedies Suggests People TAKE LESS 2Help Remedies Suggests People TAKE LESS 3Global Eyeglasses Industry 2Global Eyeglasses Industry 3Global Eyeglasses Industry 4Global Eyeglasses Industry 5Global Eyeglasses Industry 6Global Eyeglasses Industry 7Global Eyeglasses Industry 8Global Eyeglasses Industry 9Global Eyeglasses Industry 10Global Eyeglasses Industry 11Global Eyeglasses Industry 12Global Eyeglasses Industry 13
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 With ... dry in most parts of the United States, people ... conditioned rooms. Despite the obvious benefits of air conditioning, ... effects, including dry eye, dehydration and allergic reactions. Fresh ... Hour™ Power of Water® radio show, will discuss the ...
(Date:6/2/2015)... Bank, New Jersey (PRWEB) June 02, 2015 ... New Jersey’s largest nonprofit provider of home health ... appointment of its President and CEO, Steve Landers, ... America's (VNAA) Board of Directors. , VNAA ... that supports, promotes and advances mission driven, nonprofit ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Mercy Health ... serving Ohio and Kentucky – has devoted the seventh ... videos to skin cancer prevention. One in five Americans ... on Mercy Health’s YouTube channel, a Mercy Health expert ... are the main causes of skin cancer? , ...
(Date:6/2/2015)... 2015 First Choice Emergency Room ... in the United States, named Kenneth Alan Totz, D.O.as ... Road facility. , “We are pleased to announce ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director ... received his undergraduate degree from St. Edwards University in ...
(Date:6/2/2015)... Phoenix, AZ (PRWEB) June 02, 2015 ... Iowa community, has granted $70,000 to the UNMC to support ... NFL Kicker Billy Cundiff, a member of the Colleen’s Dream ... grant was the biggest to date for Colleen’s Dream ... Dr. Wang in Omaha. , “Dr. Wang is a rising ...
Breaking Medicine News(10 mins):Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 3Health News:Video provides helpful information about skin cancer prevention 2Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... participated in a cardiac-rehab program after a heart attack had ... the same age and sex who had not had a ... that occurred among patients in their study were due to ... involved about 1,800 patients. Nearly 60 percent participated in cardiac ...
... substantial morbidity and mortality and the incidence of MRSA ... to prevent the spread of MRSA including better hand ... the detection and isolation of infected patients. ... were done looking at reducing the spread of MRSA. ...
... reveals women suffering from extremely low body fat whether ... may benefit from treatment with the appetite-and-weight-regulation hormone ... in treating some instances of infertility. ,Leptin is ... stream, where it then travels to the brain and ...
... point to seek mental counseling. Experts say diabetics under ... because of unhealthy habits they implement to deal with ... showed nearly 13 percent of respondents experience psychological symptoms ... under mental distress are more likely than non-stressed diabetics ...
... recent study, a poor oral health diagnosis was a ... such as // high levels of fibrinogen (a clotting ... ,Researchers compared the oral health data of 256 ... characteristics. Results of the study show the strongest predictor ...
... new study shows consuming foods or supplements containing the omega-3 ... to avoid Alzheimer’s disease // even if you carry a ... study researchers first bred mice to carry the gene known ... various environmental factors affecting the symptoms were studied but the ...
Cached Medicine News:
Straight shafts with teeth and 5 mm tying platform. Wide serrated handle with polished finish. Teeth: 0.3 mm. Manufactured in titanium....
Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish....
Ergotec Vetriretinal Instrument System. Fine angled tips (3 mm). 20 gauge shaft length with black tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Medicine Products: